COVID-19: Your safety is our priority. Amidst the COVID-19 outbreak, we are doing our part to keep our clients and team members safe and healthy. The wheels of justice are still moving, but you can stay home while we fight for you. Learn More about the precautions Whitley Law Firm is taking to minimize the spread of COVID-19 and read more about Frequently Asked Questions regarding how the outbreak could affect your case.

Lawsuit Against Gilead Sciences Claims Misconduct with HIV Medication

Lawsuit Against Gilead Sciences Claims Misconduct with HIV Medication

Multiple lawsuits have been filed against the pharmaceutical producer Gilead Sciences, alleging that the company did not inform consumers of potential risks or side effects of their HIV medication, tenofovir disoproxil fumarate (TDF). The nationwide lawsuits also claim that the company did not advise consumers that there was a safer alternative to TDF available, known as tenofovir alafenamide fumarate (TAF).

Lawsuits filed by over 130 patients in 12 states claim that Gilead withheld TAF-based treatment from consumers who were already receiving treatment with TDF, until after the original patent on TDF expired. This decision by Gilead would allow the pharmaceutical company to shift its primary profits to TAF from TDF, which can now be manufactured by other pharmaceutical companies.

History of TDF

TDF-based HIV treatment was approved by the Food and Drug Administration (FDA) in 2001 and was meant to work in tandem with another HIV treatment option to prevent the virus from multiplying, essentially allowing a person’s immune system to control the infection better. The FDA then approved TAF-based HIV treatment in 2015 with a lower dose—and decreased side effects— from the previously-approved TDF treatment.

However, some individuals who took TDF medications to treat HIV, such as Truvada, Viread, Atripla, Complera, and Stribild, claimed they suffered numerous injuries, such as loss of bone density or kidney disease, due to the medication. Furthermore, these claims against the company say that Gilead stalled research and production of TAF-based drugs Odefsey, Descovy, and Genvoya so that they could release the drug after their patent on TDF expired.

Contact an Attorney Today

If you or someone you know has taken TDF-based HIV treatment and has experienced bone density loss, kidney disease, or another complication, it is important for you to seek legal counsel. The experienced attorneys at the Whitley Law Firm understand the complexities that come with pursuing legal action against large companies, and we could work tirelessly to establish a claim requesting full and fair compensation for your losses.